专家问答：支持线上顾问委员会并提高 KOL 参与度

虚拟顾问委员会正成为寻求有效吸引关键意见领袖 (KOL) 的製药公司的重要工具。透过利用数位平台，虚拟咨询委员会可以实现即时讨论、全球参与和简化决策。

在本报告中，我们采访了 Republic M! 的虚拟大客户经理 John Halladay。小组讨论了虚拟董事会不断扩大的角色、其缺点和好处，以及公司如何优化其影响力。

报告内容

• 与传统的面对面会议相比，虚拟顾问委员会如何改变製药公司与 KOL 互动的方式
• 虚拟顾问委员会在增强 KOL 参与度和参与度方面的潜在优势
• 虚拟顾问委员会可以使用哪些策略来提供符合 KOL 期望和兴趣的价值？
• 我们如何能最大限度地参与虚拟顾问委员会？
• 可以采取哪些方法来激发为期数週的虚拟顾问委员会会议的参与度？
• 您可以提前做些什么来增加虚拟顾问委员会会议期间的参与度？
• 虚拟顾问委员会会议结束后，哪些后续活动和参与策略可以帮助 KOL 保持参与度和积极性？
• 虚拟平台需要具备哪些重要功能才能满足顾问委员会会议的特定参与要求？
• 虚拟顾问委员会如何提供自发性、非脚本式对话的机会，同时仍保持结构化的议程？
• 如果 KOL 要求就特定主题进行更深入的讨论，公司如何准备在虚拟顾问委员会会议期间提供额外的材料或资讯？
• 可以使用哪些指标和回馈机制来评估 KOL 的参与度，以及公司可以如何根据这些回馈采取行动来增强未来的参与度？
• KOL 参与虚拟顾问委员会面临的 3 大课题
• 您希望看到虚拟顾问委员会做出哪些改变，以进一步增强 KOL 的参与度？
• 在虚拟顾问委员会时代增强 KOL 参与度

Virtual advisory boards are becoming an essential tool for pharmaceutical companies seeking to engage key opinion leaders (KOLs) efficiently and effectively. By leveraging digital platforms, these virtual boards allow for real-time discussions, global participation and streamlined decision making - without the logistical challenges of in-person meetings.

FirstWord spoke with John Halladay, virtual key account manager at Republic M! Group, about the growing role of virtual advisory boards, their drawbacks and advantages, and how companies can optimise their impact.

Key Questions Answered:

• How have virtual advisory boards changed the way pharmaceutical companies engage with KOLs compared with traditional, in-person meetings?
• What are some potential advantages of virtual advisory boards for enhancing KOL engagement and participation?
• What strategies have been effective during virtual advisory boards for providing value that aligns with KOLs' expectations and interests?
• What methods can be used to maximise engagement during virtual advisory boards?
• What approaches have been beneficial for eliciting engagement from virtual advisory boards that span several weeks?
• What can be done prior to the virtual advisory board to increase engagement during the event?
• What follow-up activities or engagement strategies can help maintain KOL involvement and collaboration after the virtual advisory board concludes?
• What features are important for a virtual platform to meet the specific engagement requirements of an advisory board meeting?
• How can virtual advisory boards incorporate opportunities for spontaneous, off-script conversations while still maintaining a structured agenda?
• How might companies prepare to provide additional materials or information during a virtual advisory board if KOLs request more detailed discussion on specific topics?
• What metrics or feedback mechanisms can be used to assess KOL engagement, and how can companies act on this feedback to enhance future engagement?
• What are the three biggest challenges to KOL engagement in virtual advisory boards?
• What changes do you anticipate in virtual advisory boards to further enhance KOL engagement?
• Do you have any concluding thoughts on the topic of enhancing KOL engagement in the era of virtual advisory boards?

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.